Shots:

• The approval is based on P-III ATLAS- FLAIR and ATLAS-2M studies assessing Vocabria (cabotegravir injection and tablets)  + Janssen’s Rekambys (rilpivirine inj.) or Edurant (rilpivirine tablets) in 1200+ patients for HIV-1 infection in adults who are virologically suppressed
• The first long-acting injectable can enable people living with HIV to reduce the days they receive treatment from 365 to 12 or 6/year. Most of the clinical trial patients who tried the treatment over their previous daily oral therapy preferred the new treatment
• The approval marks the second approval of the long-acting regimen of cabotegravir and rilpivirine- with once-monthly dosing licensed by Health Canada under the brand name Cabenuva

 ­ Ref: Businesswire | Image: The Pharma Letter